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Abstract 
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Leap-In transposase process Leap-In transposase benefits 
The generation of stable cell lines is critical for the 
commercial production of protein therapeutics. 
Current methodologies to introduce engineered 
recombinant genes into production strains relies 
on homologous recombination, a method limited 
by poor integration rates (<<1%), concatemer 
formation and common transgene 







has identified and engineered two orthologous 
transposases, designated Leap-In 1 (from frog) 
and Leap-In 2 (from insect), that stably integrate 
synthetic transposons into the host genome with 
close to 100% integration frequency and an 
absolute minimum of concatemers or other 
genetic instabilities. Each synthetic transposon 
can encode up to 4 unique open reading frames 
(ORFs) flanked by inverted terminal repeats 
 Transposon and 
transposase (as mRNA) 
co-transfected into 
target cell 
 Broad host cell range 
 ATUM uses 2 in-house 
cell lines, both with full 
traceability 
 Single copies of entire 
transposon are 
independently 
integrated by a “cut 
and paste” 
mechanism into 
multiple sites across 
the host genome 
 48 hours post 
transfection, no 
Stable pools 
Stable pool ranking 
Clonal cell line 
generation 
Application - optimized expression constructs 
recognized by the cognate transposase. Each 
ORF is under discrete expression control thereby 
enabling tuning of expression ratios by 
adjustment of each ORF independently. Leap-In 
transposases speed cell recovery times, enabling 
the generation of high expressing stable pools (up 
to 5g/L) in as little as 2 weeks post transfection. 
 HD-BIOP3 GS null 
(Horizon Discovery) 
 DG44 DHFR null 
(Prof. Lawrence 
Chasin) 
mRNA or  transposase 
are detectable Stability testing 
 
1 Shortened timelines 
Research Cell Bank 
 
2 
 Up to 4 open reading frames under 
independent expression control. 
 No size limit for synthetic transposon. 
 Multiple, parallel selection stringencies. 
 High productivities in stable pools up to 5g/l 
and clonal up to 6.5g/l. 
Adjustment of expression ratios for 2-, 3- and 4-ORF vectors HD-BIOP3 GS null CHO-K1 cell line from Horizon Discovery was co-transfected with 
ATUM’s transposase and transposons with diDerent vector and antibody 
Transposases speed cell 
pool recovery post-
transfection. 
2 ORFs 4 ORFs 
combinations to reach the highest specific productivity without compromising 
product quality.  Stable pools were established and productivity measured at day 14 
in non-optimized small scale shake flask or deep-well cultures. 
Upper graph - Under typical selection conditions (strong GS promoter, 50 µM MSX), cell pools 
created using tranposases recover viability >7 days faster than cell pools created by random 
integration. 
Lower graph - Under drug-free selection conditions (attenuated GS promoter), cell pools 
created using transposases recover viability in ~ 3 weeks, whereas cell pools created by random 
integration fail to recover. 
Screening and selection of clones expressing transposon-based antibody construct 
3 ORFs 
Two identical ORFs coding for a secreted protein were tagged with V5 (ORF1) 
or FLAG (ORF2).  A combination of vector elements were utilized to control 
the ratio of expression of ORF2 to ORF1.  Expression ratios of ORF2 : ORF1 
between 2.5 : 1 and 1 : 1.5 were demonstrated. 
ORFs encoding 3 or 4 fluorescent proteins were cloned into six diDerent 3-ORF vectors, and a single 4-
ORF vector. Fluorescence was measured at the stable pool stage. For the 3-ORF vector, various ratios 
of all three ORFs were achieved. For the 4-ORF vector, a 4-fold range of expression was observed be-
tween the diDerent ORFs. 
 Consistent ranking of highly productive 
candidates = only a small number of clones 
need to be screened. 
 Product quality attributes are consistent 
from pools to clones, enabling early initiation 























 Top 166 clones from stable pools  
 20 days in static 96-well plate 
with feeding 
 Top 22 clones of previous 166 
 7 days in 24-deep well plate 
fed batch culture 
 Top 8 clones of previous 22 
 14 days in 125 ml flask, fed 
batch, non-optimized culture 
Stable integration combined with structural integrity 
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Clonal cell lines generated using Leap-In transposases exhibit 
genetic stability and stable productivity over 60 population 
doublings. 
1:1 correlation between copy number and specific productivity in transposase 
mediated DG44 stable pools. 
Stable pools derived from the transposase-mediated integration of an antibody expression cassette in DG44 cells, were grown under 
Over 96% of expression 
cassettes integrated 




An antibody expression construct was transfected into HD-BIOP3 GS null CHOK1 cells (Horizon 
Discovery) in the presence (+ transposase) or absence (- transposase) of Leap-In transposase. 
Nine CHO GS KO clones, derived from the transposase-mediated integration of an antibody expression 
cassette, were grown in 24-deep well plate for 60 generations (population doublings (PD)) in the presence (-Gln) 
and absence (+Gln) of selection.  Productivity and integrated copy number of clones aOer 60 PD were compared 
fed-batch conditions.  Productivity and copy number were measured.  The correlation between copy number and specific 
productivity indicates that each integrated copy is intact and functional. 
Foot-print free excision of transposon from host genome. 
A synthetic transposon (RFP gene flanked by 
Leap-In 1 ITR’s inside a GFP gene flanked by 
Leap-In 2 ITR’s) was integrated into CHO cells 
using Leap-In 2 transposase. Cells exhibited 
red fluorescence as RFP is expressed.  
Typical timeline of cell line development at ATUM 
Targeted Locus Amplification was used to analyze the structural integrity of expression cassette 
integrations. 
to T0. No significant change in productivity or copy number under the  with glutamine (+Gln) and minus 
glutamine (-Gln) growth conditions were observed compared to T0.  
Excision ePciency of wild type and engineered hyperactive 
Leap-In® 1 transposases 
Cells transfected with Leap-In 1 mRNA.  
Leap-In 1 transposase excised RFP at 
cognate ITRs. 
Cells exhibited green fluorescence as 
intact GFP is expressed 
 Stable pool-derived protein is available as early as 2 weeks post transfection. 
 Clonal cell line without stability information, available as early as 12 weeks post
-transfection. Hyperactive transposase variants designed using ProteinGPS® demonstrate foot-print free excision.  Variants 
Hyperactive transposase variants 
Studies are currently ongoing  to demonstrate that integration of single 
copies of transposons is possible. 
 RCBs (Research Cell Banks) released as early as 20 weeks post-transfection. 
were ranked by excision ePciency measured as per figure on leO. DiDerent concentrations of hyperactive 
transposase mRNA demonstrated a dose response.  Hyperactive transposase variants tested show an 
approximately 80-fold higher activity compared to wild type in this assay. 
